# The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

> **NCT04591431** · PHASE2 · UNKNOWN · sponsor: **Fondazione per la Medicina Personalizzata** · enrollment: 400 (actual)

## Conditions studied

- Breast Cancer
- Gastrointestinal Cancer
- Non Small Cell Lung Cancer
- Other Cancer

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Trastuzumab
- **DRUG:** Trastuzumab emtansine
- **DRUG:** Pertuzumab
- **DRUG:** Lapatinib
- **DRUG:** Everolimus
- **DRUG:** Vemurafenib
- **DRUG:** Cobimetinib
- **DRUG:** Alectinib
- **DRUG:** Brigatinib
- **DRUG:** Palbociclib
- **DRUG:** Ponatinib
- **DRUG:** Vismogedib
- **DRUG:** Itacitinib
- **DRUG:** Ipatasertib
- **DRUG:** Entrectinib
- **DRUG:** Atezolizumab
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DRUG:** Pemigatinib

## Key facts

- **NCT ID:** NCT04591431
- **Lead sponsor:** Fondazione per la Medicina Personalizzata
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-07
- **Primary completion:** 2024-12
- **Final completion:** 2025-06
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2023-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04591431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04591431, "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04591431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*